| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-04-2549 |
| P698 | PubMed publication ID | 15958649 |
| P50 | author | David S. Alberts | Q124526404 |
| P2093 | author name string | James Ranger-Moore | |
| James A Crowell | |||
| H-H Sherry Chow | |||
| Yukihiko Hara | |||
| Iman A Hakim | |||
| Donna R Vining | |||
| Wade M Chew | |||
| Catherine A Celaya | |||
| Steven R Rodney | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tea catechin | Q68321158 |
| tea | Q6097 | ||
| bioavailability | Q461809 | ||
| P304 | page(s) | 4627-4633 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals | |
| P478 | volume | 11 |
| Q39707051 | (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells |
| Q47820957 | A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers |
| Q28393278 | A multi-targeted approach to suppress tumor-promoting inflammation |
| Q50524118 | A preliminary investigation of the impact of catechol-O-methyltransferase genotype on the absorption and metabolism of green tea catechins. |
| Q37871561 | Adverse effects of concentrated green tea extracts |
| Q34143965 | Analysis of the effect of the active compound of green tea (EGCG) on the proliferation of peripheral blood mononuclear cells |
| Q35834584 | Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy |
| Q27024257 | Anticancer activity of green tea polyphenols in prostate gland |
| Q39184401 | Antifibrotic properties of epigallocatechin-3-gallate in endometriosis |
| Q24652332 | Antimicrobial properties of green tea catechins |
| Q58802996 | Antioxidants from Plants Protect against Skin Photoaging |
| Q40919189 | Bacterial thioredoxin and thioredoxin reductase as mediators for epigallocatechin 3-gallate-induced antimicrobial action |
| Q38245598 | Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update |
| Q37237422 | Bortezomib and EGCG: no green tea for you? |
| Q28076334 | Cancer Preventive Activities of Tea Catechins |
| Q33693371 | Cancer prevention by tea: animal studies, molecular mechanisms and human relevance |
| Q41256962 | Capsule shell material impacts the in vitro disintegration and dissolution behaviour of a green tea extract |
| Q40420426 | Chemoprevention in African American Men With Prostate Cancer |
| Q35928052 | Chemoprevention in gastrointestinal physiology and disease. Targeting the progression of cancer with natural products: a focus on gastrointestinal cancer |
| Q38093214 | Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer |
| Q38579658 | Chronic treatment with epigallocatechin gallate reduces motor hyperactivity and affects in vitro tested intestinal motility of spontaneously hypertensive rats. |
| Q90387134 | Clinically Relevant Herb-Micronutrient Interactions: When Botanicals, Minerals, and Vitamins Collide |
| Q50231312 | Combinational enhancing effects of formulation and encapsulation on digestive stability and intestinal transport of green tea catechins |
| Q45502853 | Comparison of catechin profiles in human plasma and urine after single dosing and regular intake of green tea (Camellia sinensis). |
| Q36051522 | Complementary and alternative medicines in prostate cancer: from bench to bedside? |
| Q36335599 | Coordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin |
| Q64256809 | Daily Green Tea Infusions in Hypercalciuric Renal Stone Patients: No Evidence for Increased Stone Risk Factors or Oxalate-Dependent Stones |
| Q39884722 | Development and validation of an algorithm to establish a total antioxidant capacity database of the US diet |
| Q46432293 | Dietary Polyphenols and Their Biological Significance |
| Q38211784 | Dietary factors affecting polyphenol bioavailability |
| Q35872264 | Discovery of ethyl urea derivatives as inhibitors of islet amyloid polypeptide fibrillization and cytotoxicity. |
| Q45241260 | Dose-response plasma appearance of green tea catechins in adults |
| Q36168253 | EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism |
| Q50534664 | Effect of Tea Beverages on Aldehyde Oxidase Activity |
| Q36837995 | Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice |
| Q37380434 | Effect of green tea catechins and hydrolyzable tannins on benzo[a]pyrene-induced DNA adducts and structure-activity relationship |
| Q53758859 | Effect of hydroxypropyl methyl cellulose phthalate coating on digestive stability and intestinal transport of green tea catechins. |
| Q34799545 | Effect of ingested lipids on drug dissolution and release with concurrent digestion: a modeling approach |
| Q36913657 | Effects of (-)-gallocatechin-3-gallate on tetrodotoxin-resistant voltage-gated sodium channels in rat dorsal root ganglion neurons |
| Q39896516 | Effects of green tea extract on lung cancer A549 cells: proteomic identification of proteins associated with cell migration |
| Q37390521 | Effects of the green tea catechin (-)-epigallocatechin gallate on Trypanosoma brucei |
| Q43134213 | Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. |
| Q39609996 | Enhanced uptake and transport of (+)-catechin and (-)-epigallocatechin gallate in niosomal formulation by human intestinal Caco-2 cells |
| Q33655389 | Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail |
| Q36482815 | Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus |
| Q36217669 | Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis. |
| Q35234948 | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. |
| Q37204674 | Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs |
| Q36335008 | Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans |
| Q27329920 | Food-associated stimuli enhance barrier properties of gastrointestinal mucus |
| Q41870606 | Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green tea |
| Q36405292 | Green Tea Catechin, EGCG, Suppresses PCB 102-Induced Proliferation in Estrogen-Sensitive Breast Cancer Cells |
| Q33845027 | Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. |
| Q33712795 | Green Tea Extract (GTE) improves differentiation in human osteoblasts during oxidative stress |
| Q36334971 | Green Tea Extract Induces the Resistance of Caenorhabditis elegans against Oxidative Stress |
| Q58769386 | Green Tea Extract Preserves Neuromuscular Activation and Muscle Damage Markers in Athletes Under Cumulative Fatigue |
| Q37596592 | Green tea (Camellia sinensis) catechins and vascular function. |
| Q37308282 | Green tea and prostate cancer: from bench to clinic |
| Q24604945 | Green tea and the risk of gastric cancer: epidemiological evidence |
| Q50239189 | Green tea beverages enriched with catechins with a galloyl moiety reduce body fat in moderately obese adults: a randomized double-blind placebo-controlled trial |
| Q34008679 | Green tea catechins are potent sensitizers of ryanodine receptor type 1 (RyR1). |
| Q38147993 | Green tea catechins: a fresh flavor to anticancer therapy |
| Q28821563 | Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma |
| Q43088546 | Green tea extract as a local drug therapy on periodontitis patients with diabetes mellitus: A randomized case-control study. |
| Q46368445 | Green tea extract does not affect exogenous glucose appearance but reduces insulinemia with glucose ingestion in exercise recovery |
| Q61454323 | Green tea extract for prevention of prostate cancer progression in patients on active surveillance |
| Q38008090 | Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. |
| Q50482191 | Green tea formulations with vitamin C and xylitol on enhanced intestinal transport of green tea catechins. |
| Q33923444 | Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise |
| Q37461384 | Green tea polyphenols for prostate cancer chemoprevention: a translational perspective |
| Q33623283 | Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome |
| Q39983590 | Growth inhibition of colon cancer cells by polyisoprenylated benzophenones is associated with induction of the endoplasmic reticulum response |
| Q91817170 | Health Functions and Related Molecular Mechanisms of Tea Components: An Update Review |
| Q37387019 | Hepatotoxicity from green tea: a review of the literature and two unpublished cases |
| Q38481053 | Hepatotoxicity of green tea: an update |
| Q36226597 | Impact of Proteins on the Uptake, Distribution, and Excretion of Phenolics in the Human Body |
| Q39429323 | Inhibition of glycoprotein synthesis in the endoplasmic reticulum as a novel anticancer mechanism of (-)-epigallocatechin-3-gallate |
| Q46957675 | Inhibition of intestinal tumorigenesis in Apc(min/+) mice by green tea polyphenols (polyphenon E) and individual catechins |
| Q35187885 | Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. |
| Q42233550 | Inhibitory effects of daiokanzoto (da-huang-gan-cao-tang) on p-glycoprotein |
| Q33652893 | Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity |
| Q47701507 | Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers |
| Q38847316 | Lipid-soluble green tea extract: Genotoxicity and subchronic toxicity studies. |
| Q39542245 | Minor effects of green tea catechin supplementation on cardiovascular risk markers in active older people: a randomized controlled trial |
| Q37576761 | Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention |
| Q42856907 | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (−)-epigallocatechin-3-gallate |
| Q50201369 | Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1β signaling in rheumatoid arthritis synovial fibroblasts. |
| Q58294557 | N- and S-homocysteinylation reduce the binding of human serum albumin to catechins |
| Q24619151 | New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer |
| Q39959197 | Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable |
| Q26740187 | Novel drugs that target the metabolic reprogramming in renal cell cancer |
| Q33676445 | Nutraceuticals in hypercholesterolaemia: an overview |
| Q35000546 | Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model |
| Q34595991 | Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas |
| Q37882092 | Pharmacokinetic and chemoprevention studies on tea in humans |
| Q30252185 | Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia |
| Q46463218 | Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis |
| Q37306304 | Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia |
| Q38672179 | Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans |
| Q42944178 | Plasma appearance and correlation between coffee and green tea metabolites in human subjects |
| Q50529123 | Plasma pharmacokinetics of catechin metabolite 4'-O-Me-EGC in healthy humans. |
| Q33680143 | Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K(ATP) channel activation in isolated rat hearts |
| Q30989271 | Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies. |
| Q50146225 | Population nutrikinetics of green tea extract. |
| Q90369643 | Practical Application of "About Herbs" Website: Herbs and Dietary Supplement Use in Oncology Settings |
| Q37150917 | Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy |
| Q35549412 | Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. |
| Q37584789 | Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. |
| Q49714721 | Quercetin and fisetin enhanced the small intestine cellular uptake and plasma levels of epi-catechins in in vitro and in vivo models. |
| Q36132629 | Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. |
| Q37684414 | Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins |
| Q24616890 | Recent advances on tea polyphenols |
| Q26775886 | Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease models |
| Q41679554 | Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia |
| Q34008178 | Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice |
| Q37165492 | Safety of green tea extracts : a systematic review by the US Pharmacopeia |
| Q39333905 | Short-term green tea extract supplementation attenuates the postprandial blood glucose and insulin response following exercise in overweight men. |
| Q38718180 | Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation induced skin damage. |
| Q42082283 | Stability of Polyphenols Epigallocatechin Gallate and Pentagalloyl Glucose in a Simulated Digestive System |
| Q38532720 | Tea Polyphenols in Parkinson's Disease |
| Q38219136 | Tea and its consumption: benefits and risks. |
| Q28477337 | Tea consumption enhances endothelial-dependent vasodilation; a meta-analysis |
| Q36995186 | The Effect of Camellia sinensis on Wound Healing Potential in an Animal Model. |
| Q52726876 | The Effect of Tomatine on Gene Expression and Cell Monolayer Integrity in Caco-2. |
| Q50534157 | The Effects of Green Tea Extract on Working Memory in Healthy Women. |
| Q35836863 | The challenge of developing green tea polyphenols as therapeutic agents |
| Q38003181 | The effects of green tea polyphenols on drug metabolism |
| Q39962219 | The impact of the catechol-O-methyltransferase genotype on the acute responsiveness of vascular reactivity to a green tea extract |
| Q37910326 | The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms |
| Q42947442 | The regular consumption of a polyphenol-rich apple does not influence endothelial function: a randomised double-blind trial in hypercholesterolemic adults. |
| Q34206372 | The safety and regulation of natural products used as foods and food ingredients. |
| Q51244401 | The safety of green tea and green tea extracts consumption in adults - Results of a systematic review. |
| Q35967627 | The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. |
| Q37019265 | The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial |
| Q36778434 | Topical Application of Green Tea Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) for Prevention of Recurrent Oral Neoplastic Lesions |
| Q37091686 | Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study |
| Q90094530 | United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts |
| Q50506744 | Updated bioavailability and 48 h excretion profile of flavan-3-ols from green tea in humans. |
| Q24618321 | White Tea Extract Induces Apoptosis in Non–Small Cell Lung Cancer Cells: the Role of Peroxisome Proliferator-Activated Receptor-γ and 15-Lipoxygenases |
Search more.